Sentences with phrase «at tumor sites»

Stephan realized that he could load anti-tumor T cells — immune cells specially engineered to recognize and destroy cancers — into dissolving polymer scaffolds and place them directly at tumor sites.

One drug attacks cancer cells; the other inhibits cancer cell formation and the growth of blood vessels at tumor sites.

These particles congregate at tumor sites, where MMPs cleave hundreds of peptides, which accumulate in the kidneys and are excreted in the urine.

«This combinational treatment also was well tolerated and enhanced the number of CD8 T cells at the tumor site.

The problem previous researchers couldn't overcome was how to keep the herpes viruses at the tumor site long enough to work.

The biomarkers would accumulate at the tumor site.

However, the reality is that nanocarriers may not always reach their intended target in sufficient numbers because of a constraint on their ability to transit through the blood vessel wall at the tumor site, leading the encapsulated drugs to be diverted or lost before they can deliver their payload.

«The antibody blocks the interaction and allows those T - cells that are already at the tumor site to be more effective.»

In contrast, mice treated with antibody - expressing NSCs showed anti-HER2 IgG at the tumor site, but no human IgG was detectable in the blood (data not shown).

Our ability to detect anti-HER2 antibody at the tumor site but not in the blood of NSC - treated mice suggests that this approach could have robust localized anti-tumor effect, while minimizing the systemic toxicity associated with traditional trastuzumab therapy.

PET scans revealed a 21.8 % average decrease in glucose uptake at the tumor site in both patients.

Chemotherapy Chemotherapy is used to treat cancer at the tumor site, as well as the cancer that may have spread through the body.

The treatment is not painful, but does have some side effects, including hair loss at the tumor site, skin burn similar to sunburn, and occasionally ulcerated areas.

Not exact matches

«Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning.»

When the dendritic cells are activated, they train T cells — their allies in the adaptive arm of the immune system — to attack cancer cells anywhere in the body, whether at the site of the original tumor or distant metastases.

«Most cancer patients are actually at risk of having their tumor spread to multiple sites,» Dr. Massagué notes.

«The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,» he said.

With a grant from the Morris Animal Foundation, Antczak, his collaborators Samantha Brooks and Ann Staiger from the University of Florida, and the rest of the team applied a genomewide association study to compare the genetic makeup of horses with and without sarcoid tumors at more than 50,000 sites in the equine genome.

Studies in cancer patients indicate reduced rates of relapse when patients are pretreated with epigenetic drugs due to its far - reaching capabilities; killing progenitor cells at the site of the tumor, in circulation, or at a distant site.

«We wanted to utilize platelets» intrinsic tendencies to accumulate at wounds and to interact with circulating tumor cells, for targeted delivery of immune checkpoint inhibitors» said Gu, «Interestingly, we found the antibody can be promoted to release from activated platelets in the surgical site, due to generation of small platelet - derived microparticles upon the platelet activation.

Cancer can become deadly after surgery to remove a primary tumor because of the possibility of recurrence of the cancer at the surgery site and other parts of the body.

Metastasis, or cancer spread by the formation of tumors at new sites, is generally what makes cancers deadly because surgery and other treatments are unlikely to find and destroy every cancer cell.

The team of medical and engineering researchers at The Ohio State University previously determined that modifying a single gene to reduce this protein's level in breast cancer cells lowered the cells» ability to migrate away from the tumor site.

Eventually some tumor cells may break off and establish new growths (metastases) at distant sites.

Similar to humans, the mice developed tumors at secondary sites including the liver, lung, peritoneum, and diaphragm.

«The recent discovery of tumor - promoting milieus, referred to as metastatic niches, that are established at distant sites prior to or upon the arrival of disseminated tumor cells could explain cancer cells that relapse early, but in late relapsing populations, what tumor cells do from the time of dissemination to the time they become clinically detectable has been a big question.»

Though vestibular schwannomas affecting both sides are the hallmark of neurofibromatosis type 2 (NF2), a genetic disorder causing tumors to grow at multiple sites throughout a person's life, vestibular schwannomas may also occur sporadically, and on one side only.

Importantly, it's secretion from normal cells can be induced by activating p53 so that Par - 4 enters circulation, thereby potentially targeting tumor cells at distant sites.

Delivery of XL184 directly to the tumor site produced these promising results at a dosage level less than one thousandth of what is used in oral therapy, with little or no toxicity.

We describe an experimental model system that definitively links surgery and the subsequent wound - healing response to the outgrowth of tumor cells at distant anatomical sites.

«SynNotch receptors essentially allow us to confine the T cell response at the site of disease with the goal of enhancing the ability of the T cell to, for example, overcome the inhospitable microenvironment of a solid tumor.

This allows cancer cells to break off from tumors, spread throughout the body (in blood or other fluid) and form new tumors at distant sites — a process called metastasis.

Testosterone treatment alone did not induce specific tumors at other sites, but compared with control rats, it caused a significant increase in the number of rats with malignant tumors at any site.

They also captured information on the presence of immune cells at the site of the tumor.

And because tumors typically have a leaky, ill - formed vasculature, the particles tend to leak out at the site of cancer tissue and be picked up and internalized inside tumor cells.

This helps ensure selective drug targeting only at the site of the tumor.

The therapy not only killed cells at the primary tumor site, but also in distant metastases by «bystander» antitumor activity driven by the secreted MDA - 7 / IL - 24 protein.

Researchers at the University of Oxford and Ulster are investigating how to re-oxygenate tumors with a drink that could deliver extra oxygen to the site of the tumor, allowing radiotherapy and chemotherapy to deliver a knock - out blow.

The prognosis for metastatic cancer (also called stage IV cancer) is generally poor, so a technique that could detect these circulating tumor cells before they have a chance to form new colonies of tumors at distant sites could greatly increase a patient's survival odds.

However, metastatic tumors continued to appear over time in untreated sites likely because those tumors were so small at initial treatment that they were not detected.

«Historically, when treating early lung cancer with radiotherapy, progression at the site of the primary tumor was the most common failure resulting in suffering and death,» said lead study author Robert Timmerman, MD, professor and vice chair of the department of radiation oncology at the University of Texas Southwestern Medical Center in Dallas.

A new study shows that a 70 - year - old malaria drug can block immune cells in the liver so nanoparticles can arrive at their intended tumor site, overcoming a significant hurdle of targeted drug delivery, according to a team of researchers led by Houston Methodist.

Even in nanomedicine, which is one of the best new methods for delivering drugs to a tumor, only about one percent of a dose of nanoparticles will successfully arrive at the intended tumor site, while the rest are filtered out by the immune cells of the liver and spleen.

This long - term analysis confirms that treated tumors did not reappear at the original site; and late toxicity, beyond what was seen in the initial report, did not appear.

The Ludwig Center at the University of Chicago --- under the direction of Ralph Weichselbaum, MD, the Daniel K. Ludwig Professor and Chair of the Department of Radiation and Cellular Oncology, and Geoffrey Greene, PhD, the Daniel K. Ludwig Professor in the Ben May Cancer Research Institute at the University of Chicago — will focus on metastasis, the process by which cancer cells migrate from a primary tumor to multiple distant sites.

Additional evidence supporting the tumor - promoting role of inflammation is the observation that individuals with chronic inflammation are more susceptible to cancers at the site of that inflammation — e.g. patients with Crohn's disease show increased incidence of colorectal cancer.

Furthermore, the genetic and expression profiles of malignant cells vary within individual tumors, between tumors at different sites within the same patient, and among tumors from different patients.

In mice, the study found this helped kill tumors hiding elsewhere in the body — not just at the site of the injection.

Passive targeting nanomedicines are not enough to improve the drug accumulation at the tumor target site for the high hypovascularization level.

There was no difference in lactate dehydrogenase, the number of metastatic sites, prior adjuvant therapy, primary in place at initiation of therapy, or intent of treatment across the cohorts for right - compared with left - sided tumors.